Nico Cantone

Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas

Rishi G. Vaswani, Victor Gehling, Les A. Dakin et al. · Journal of Medicinal Chemistry · 2016 · 220 citations · Full text

Medicine, Oncology, Pharmacology +16

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

Brian K. Albrecht, Victor Gehling, Michael C. Hewitt et al. · Journal of Medicinal Chemistry · 2016 · 215 citations · Full text

Medicine, Oncology, Pharmacology +15

EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation

William D. Bradley, Shilpi Arora, Jennifer Busby et al. · Chemistry & Biology · 2014 · 148 citations

Medicine, Oncology, Pharmacology +11

A Twenty-year Experience With Endoscopic Therapy for Symptomatic Primary Sclerosing Cholangitis

Michael Glück, Nico Cantone, John J. Brandabur et al. · Journal of Clinical Gastroenterology · 2008 · 141 citations

Medicine, Internal Medicine, End-of-life Care +16

Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)

Alexander M. Taylor, Alexandre Côté, Michael C. Hewitt et al. · ACS Medicinal Chemistry Letters · 2016 · 112 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14